Search Login Register

aprepitant (Emend) Summary

Description: a bis(trifluoromethyl)morpholine; antagonist of RECEPTORS, NEUROKININ-1

Also Known As: Emend; (2R)-(1R)-3,5-bis(trifluoromethylphenyl)ethoxy)-(3S)-(4-fluoro)phenyl-4-(3-(5-oxo-1H,4H-1,2,4-triazole)methyl-morpholine; L 785,298; L-785,298; L785,298; MK 0517; MK 0869; MK 869; MK-0517; MK-0869; MK-869; MK0517; Merck brand of aprepitant; fosaprepitant; fosaprepitant dimeglumine

Networked: 378 relevant articles (116 outcomes, 120 trials/studies) for this Drug

Key Diseases for which aprepitant is Relevant

  1. Vomiting : 85 outcomes 73 studies in 264 results
  2. Nausea : 58 outcomes 54 studies in 222 results
  3. Postoperative Nausea and Vomiting (PONV) : 12 outcomes 12 studies in 35 results
  4. Neoplasms (Cancer) : 8 outcomes 16 studies in 65 results
  5. Breast Neoplasms (Breast Cancer) : 4 outcomes 7 studies in 20 results
Show All >>

Drugs Related to aprepitant

  1. Dexamethasone (Maxidex)
  2. Cisplatin (Platino)
  3. Neurokinin-1 Receptors (Neurokinin 1 Receptor)
  4. Ondansetron (Zofran)
  5. palonosetron (Aloxi)
  6. Antiemetics
  7. Granisetron (Kytril)
  8. Serotonin (5 Hydroxytryptamine)
  9. 5-HT3 Serotonin Receptors (5 HT3 Receptor)
  10. Serotonin 5-HT3 Receptor Antagonists
Show All >>

Therapies Related to aprepitant

  1. Drug Therapy (Chemotherapy)
  2. Transplants (Transplant)
  3. Hematopoietic Stem Cell Transplantation
  4. Oral Administration
  5. Injections
Show All >>

CureHunter Inc. provides medical information and specifically does NOT provide medical advice.
© Copyright 2003-2016 CureHunter Inc., MeSH copyright NLM, Journal Articles copyright original owners.